Drug Profile
PRL3 ZUMAB
Alternative Names: PRL3-ZUMABLatest Information Update: 03 Jan 2023
Price :
$50
*
At a glance
- Originator INTRA-IMMUSG
- Developer INTRA-IMMUSG; National University Hospital (Singapore)
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Solid tumours
Most Recent Events
- 03 Jan 2023 PRL3-zumab is still in phase II clinical trials for Solid tumours (Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (IV)
- 03 Jan 2023 PRL3-zumab is still in phase II trials for Solid tumours (Inoperable/Unresectable, Late-stage disease) in Singapore (IV)
- 12 Dec 2020 Phase-II clinical trials in Solid tumours (Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (IV) (NCT04452955)